Animal studies demonstrate that Ninj1 inhibition through genetic knockout or monoclonal antibodies can mitigate tissue damage and inflammation in models of pulmonary fibrosis, multiple sclerosis, and liver injury (15, 16). This evidence concerns the gene NINJ1 and multiple sclerosis.